|
|
| A Full-Service Outsourcing Partner with 97% Customer Retention | inSeption Group offers a full-service solution designed to disrupt the current outsourcing paradigm, resurrecting a common-sense approach to rebuild business trust and confidence in a client’s selected vendor. Primarily focused on oncology, hematology, neurodegenerative disorders, and rare/orphan disease indications, with a specialization in cell and gene therapy, inSeption has been a solution for its’ clients who have experienced the progressive degradation of today’s outsourcing options. Contact them. |
|
|
|
|
By Mei-Chun Yang, CEO, GlycoNex | Outsourcing antibody-drug conjugate manufacturing is the status quo. This executive explains why her company chooses to do it themselves for reasons including quality control and cost management. |
|
|
|
|
| A Guide To RTSM For Clinical Trials | Article | By Ian Davison and Marc Weinberg, Medrio | Looking ahead, the evolution of RTSM in clinical trials points towards cloud-based solutions, heightened emphasis on patient safety, and greater collaboration among stakeholders. Learn how you can prepare. |
|
|
| Optimizing Autologous Cell Therapy Clinical Trials | e-book | By Karen Ivester, inSeption Group | Delve into four articles regarding dissecting the critical resources, processes, and key stakeholders essential for the successful completion of an ACT clinical trial. |
|
|
|
|
.png){kind=logo}
